Latest Articles

Publication Date
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace

Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times

Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire

Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스

Published: May 7, 2025, noon
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial - koreabiomed.com

Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial koreabiomed.com

Published: May 7, 2025, 6:51 a.m.
Uterine fibroids are a common medical condition, and for some women it can be devastating - MSN

Uterine fibroids are a common medical condition, and for some women it can be devastating MSN

Published: April 5, 2025, 7:13 p.m.
'Ovariostasis' as the main preventive and therapeutic strategy for gynecological pathologies in women of reproductive age.

Ovariostasis is a reversible and temporary suspension of the cyclic ovarian activity, characterized by anovulation and hypogonadotropinemia (low serum concentrations of FSH and LH), which can be observed in case …

Published: April 3, 2025, midnight
Utilising Human Myometrial and Uterine Fibroid Stem Cell-Derived Three Dimentional Organoids as a Robust Model System for Understanding the Pathophysiology of Uterine Fibroids.

Uterine fibroids (UFs) are the most common benign gynecologic tumours affecting women of reproductive age. This study aims to deepen the understanding of UFs complex aetiology through harnessing the power …

Published: March 20, 2025, midnight
Analysis of risk factors for recurrence after laparoscopic myomectomy: A retrospective study.

At present, there is unclear on the risk factors of recurrence after myomectomy. In this study, we hope to provide reference for the choice of treatment for patients with uterine …

Published: March 19, 2025, 12:17 a.m.
Using electronic health record data to identify incident uterine fibroids and endometriosis within a large, urban academic medical center: a validation study.

Electronic health records (EHRs) present opportunities to study uterine fibroids uterine fibroids and endometriosis within diverse populations. When using EHR data, it is important to validate outcome classification via diagnosis …

Published: March 18, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!